Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pacing technique aims to outperform standard therapy for heart failure

NCT ID NCT07814612

Symptom relief Sponsor: Second Affiliated Hospital of Nanchang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether a pacing technique called left bundle branch area pacing, guided by detailed imaging and electrical data, can improve outcomes for people with heart failure and left bundle branch block. The trial enrolls 100 adults with non-ischemic cardiomyopathy and reduced heart function who have already taken heart failure medications for at least three months. Participants are randomly assigned to receive either the new pacing approach or standard biventricular pacing, and researchers track deaths and heart failure hospitalizations over at least a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
left bundle branch area pacing guided by multimodal data
What this could lead to
If it works, this could give heart failure patients with left bundle branch block a pacing option that uses the heart's own conduction system and may work better than standard biventricular pacing.
What could go wrong
The trial is small and early, so it may not show a clear advantage over standard pacing. The procedure can be technically difficult, and some patients may not improve even with the new approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-80 years; * Sinus rhythm, complete left bundle branch block (LBBB) fulfilling the Strauss criteria (QRS duration \>140 ms in men or \>130 ms in women); * Non-ischemic cardiomyopathy, left ventricular ejection fraction (LVEF) ≤40%, and New York Heart Association (NYHA) functional class II-IV; * Signed informed consent. * All enrolled patients received guideline-recommended pharmacological therapy for heart failure for at least 3 months. Exclusion Criteria: * Coronary CT-confirmed ischemic cardiomyopathy; * wide QRS complex with non-LBBB morphology, including right bundle branch block and nonspecific intraventricular conduction block; * persistent atrial fibrillation; * pacemaker replacement without reimplantation of ventricular leads; * patients with special conditions, such as pregnancy, gestation, and advanced malignancy. * All patients underwent detailed recording of electrophysiological pacing parameters intraoperatively and postoperatively, and monitoring for surgical complications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure progressive familial heart block, type 1A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Left bundle branch block Non-ischemic cardiomyopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

    RECRUITING

    Nanchang, Jiangxi, 330006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.